Skip to main content

Table 2 Univariate and Multivariate analysis of progression free survival (PFS) and Overall survival (OS) among all tumors

From: Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors

Variable Hazard ratio (HR) 95% confidence interval for HR p-value
Univariate analysis of PFS among all tumors
 Incomplete resection 1.66 0.30–1.17 0.13
 WHO grade3 2.91 1.34–7.26 0.0057
 C11orf95-RELA fusion 0.59 0.29–1.50 0.29
 PFA 3.30 1.69–6.72 0.0004
 1q gain 3.21 1.50–6.48 0.0037
 EZH2 high expression 1.29 0.63–2.67 0.49
 TERT high expression 1.18 0.58–2.42 0.65
 TERT UTSS high methylation 1.42 0.72–2.96 0.32
 Local radiation therapy> = 50Gy 0.73 0.37–1.46 0.37
 Chemotherapy 1.48 0.74–2.90 0.26
Multivariate analysis of PFS among all tumors
 WHO grade3 1.33 0.53–3.66 0.55
 PFA 3.09 1.48–6.81 0.0024
 1q gain 2.79 1.25–5.99 0.014
Univariate analysis of OS among all tumors
 Incomplete resection 2.22 0.17–1.09 0.077
 WHO grade3 6.31 1.84–39.6 0.0017
 C11orf95-RELA fusion 0.46 0.07–1.61 0.25
 PFA 5.47 2.16–16.7 0.0002
 1q gain 1.57 0.51–3.99 0.40
 EZH2 high expression 1.21 0.46–3.21 0.70
 TERT high expression 0.76 0.29–1.94 0.57
 TERT UTSS high methylation 1.90 0.78–5.28 0.16
 Local radiation therapy> = 50Gy 1.22 0.48–3.31 0.68
 Chemotherapy 1.86 0.74–4.62 0.18
Multivariate analysis of OS among all tumors
 WHO grade3 3.49 0.91–23.05 0.07
 PFA 3.54 1.33–11.4 0.01